225 results on '"Lartigau, E."'
Search Results
2. PO-1237 Efficacy and tolerance of stereotactic re-irradiation in the treatment of head and neck cancers
3. Braindrive : qui peut conduire parmi les patients pris en charge pour une radiothérapie cérébrale ?
4. Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial
5. Estimation de la survie globale à partir des données administratives hospitalières avec intégration des données de décès de l'INSEE : l'expérience du Centre Oscar Lambret.
6. Retour d'expérience sur le projet de chaînage entre les données hospitalières du Centre Oscar Lambret et les fichiers de décès de l'Insee
7. Place de la radiothérapie de la tumeur primitive et/ou des métastases du cancer de la prostate oligométastatique
8. PH-0498 Stereotactic body radiation therapy for the management of hepatocellular carcinoma
9. Delayed care for patients with newly diagnosed cancer due to COVID-19 and estimated impact on cancer mortality in France
10. Mucoepidermoid carcinoma of salivary glands: A French Network of Rare Head and Neck Tumors (REFCOR) prospective study of 292 cases
11. Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis
12. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group
13. PO-0974: Helical intensity-modulated radiation therapy for locally advanced breast cancer:a prospective study
14. Place et modalités de l’irradiation postopératoire dans la prise en charge des métastases cérébrales
15. 1708P Online survey on SARS-CoV-2 infections in cancer patients during a nationwide lockdown in France
16. Oncologic outcomes, prognostic factor analysis and therapeutic algorithm evaluation of head and neck mucosal melanomas in France
17. Le taux d’apoptose lymphocytaire radio-induit CD8 prédicteur de la toxicité pelvienne après radiothérapie prostatique : résultats de l’étude prospective multicentrique française
18. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial
19. L’oncologue radiothérapeute, un des acteurs du parcours du patient après cancer. Surveillance après cancer de la prostate
20. Radiothérapie stéréotaxique extra crânienne. Comment mieux protéger les tissus sains ?
21. Intracavitary Preoperative Brachytherapy Followed By Whertheim-Type Hysterectomy in Localized Cervical Cancer: Clinical Data and Toxicity Results from a Single Institution Experience
22. Magnetic Resonance Imaging Based Delta Radiomics As Biomarker for Intermediate Risk Prostate Cancer Treated By Hypofractionated Stereotactic Boost: A Phase II CKNO PRO Ancillary Study
23. EP-1257 Post-operative hypo-fractionated SBRT in a large series of patients with brain metastases
24. PO-0841 Salvage SBRT for local prostate cancer recurrence after radiotherapy: a GETUG retrospective study
25. PV-103 Linking ACROP guidelines to ICRU91: a multicentre study in lung SBRT on prescription and reporting
26. OC-0498 Results of the prospective trial evaluating radiation-induced lymphocyte apoptosis and prostate RT
27. SP-0641 Implementation and practice of SRS and SBRT: Consensus guidelines and protocols
28. Stereotactic reirradiation for local recurrence in the prostatic bed after prostatectomy: Preliminary results
29. Réirradiation stéréotaxique du lit prostatique pour récidive locale après prostatectomie et radiothérapie externe de rattrapage
30. Multidisciplinary development of the Geriatric Core Dataset for clinical research in older patients with cancer: A French initiative with international survey
31. Benefits of physical activity and sport integrated into the care pathway of oncology patient
32. PO-0742: Intensity-modulated radiotherapy for the adjuvant treatment of breast cancer: a prospective study
33. PO-0721: Multicentric experience of hypofractionated stereotactic radiotherapy for intracranial meningiomas
34. Chest Magnetic Resonance Imaging Decreases Inter-observer Variability of Gross Target Volume for Lung Tumors
35. SP-0099: What is the indication and what is the aim of clinical treatment: radiotherapy
36. EP-1093: Hypofractioned robotic stereotactic radiotherapy of Head and neck Paragangliomas
37. EP-1694: DW-MRI as a predictor of tumor response to hypofractionated stereotactic boost for prostate cancer
38. Guidelines on the standards for the training of specialised health professionals dealing with breast cancer
39. Standards, Options et Recommandations pour la prise en charge de patientes atteintes de cancer invasif du col utérin (stade non métastatique) (version abrégée)
40. Consensus Statement From the International Stereotactic Body Radiotherapy Consortium for Head and Neck Carcinoma—Technical Factors
41. Consensus Statement From the International Stereotactic Body Radiotherapy Consortium for Head and Neck Carcinoma—Patient Selection and Pre- and Post-Stereotactic Body Radiation Therapy Evaluation
42. Interstitial Brachytherapy (IBT) BOOST in the Treatment of Cancers of the Anal Canal
43. Clinical implementation of a Monte Carlo based treatment plan QA platform for validation of Cyberknife and Tomotherapy treatments
44. Organisation des sorties d’hospitalisation en cancérologie : mise en place et bilan d’utilisation du logiciel Trajectoire
45. EP-1204: Predicting toxicity after lung stereotactic radiation therapy
46. SP-0386: SBRT/SABR for oligometastatic disease
47. EP-1180: Postoperative IMRT with helical tomotherapy for breast cancer: outcome and toxicity analysis
48. EP-1455: Impact of the implementation of the radiotherapy workflow optimization software RT-Flow
49. PROCLAIM : résultats finaux de survie globale de l’essai de phase III : pemetrexed cisplatine ou étoposide cisplatine, plus radiothérapie thoracique suivie d’une chimiothérapie de consolidation dans le CBNPC non épidermoïde localement avancé
50. A biophysical model of cell evolution after cytotoxic treatments: Damage, repair and cell response
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.